Meeting highlights from the Committee for Human Medicinal Products (CHMP) 13-16 February 2012

 

London, UK (February 17, 2012) – This page lists the opinions adopted at the February 2012 meeting of the Committee for Medicinal Products for Human Use (CHMP) and other important outcomes.

 

The new format allows users to view the main opinions adopted at the meeting, along with information on referral procedures, in a clear tabular format. Users can click on the links within the page to read individual press releases and more detailed information about the opinions.

 

The new format replaces the two PDF documents that used to list each meeting’s outcome: the CHMP meeting highlights, published on the Friday following the meeting and the CHMP monthly report, published around a week later. The Agency will publish a new page following each month’s CHMP meeting.



Positive opinions on new medicines

 

Name of medicine

INN

Marketing authorisation applicant

Nimenrix

Meningococcal Group A, C, W-135 and Y conjugate vaccine

GlaxoSmithKline Biologicals S.A.

Pixuvri

Press release: European Medicines Agency recommends conditional approval of Pixuvri (pixantrone) for relapsed or refractory aggressive non-Hodgkin’s B-cell lymphoma

Pixantrone Dimaleate

CTI Life Sciences Ltd

Pyramax

Press release: European Medicines Agency recommends new anti-malaria treatment for use outside the European Union

Pyronaridine / Artesunate

Shin Poong Pharmaceutical Co., Ltd

Sancuso

Granisetron

ProStrakan Ltd



Positive opinions on generics

 

Name of medicine

INN

Marketing authorisation applicant

Capecitabine Accord

Capecitabine

Accord Healthcare Ltd

Capecitabine Krka

Capecitabine

Krka, d.d., Novo mesto

Capecitabine Teva

Capecitabine

Teva Pharma B.V.

Sabervel

Irbesartan

Pharmathen S.A.

Zoledronic acid Actavis

Zoledronic Acid

Actavis Group PTC ehf



Positive opinion on informed consent application

 

Name of medicine

INN

Marketing authorisation holder

Riluzole Zentiva

Riluzole

Pharma S.A.



Positive opinions on extensions of therapeutic indications

 

Name of medicine

INN

Marketing authorisation holder

BYETTA

Exenatide

Eli Lilly Nederland B.V.

Humira

Adalimumab

Abbott Laboratories Ltd

PegIntron

Peginterferon alfa-2b

Schering-Plough Europa

Rebetol

Ribavirin

Schering-Plough Europa

ViraferonPeg

Peginterferon alfa-2b

Schering-Plough Europa



Final opinions on safety reviews for centrally authorised medicines

 

Name of medicine

INN

Marketing authorisation holder

Aliskiren-containing medicines
Razilez, Riprazo, Sprimeo, Rasilamlo, Rasilez HCT, Riprazo HCT, Sprimeo HCT, Rasitrio

Press release: European Medicines Agency recommends new contraindications and warnings for aliskiren-containing medicines

aliskiren

Novartis Europharm Ltd



Final opinions on reviews for centrally and non-centrally authorised medicines relating to manufacturing issues

 

Name of medicine

Medicines manufactured at Ben Venu Laboratories
Angiox, Busilvex, Cayston, Ecalta, Luminity, Mepact, Soliris, Torisel, Velcade, Vibativ, Vidaza, Vistide

Press release: European Medicines Agency gives final recommendations for 12 centrally authorised medicines manufactured at Ben Venue Laboratories



Final opinions on safety reviews for centrally and non-centrally authorised medicines

 

Name of medicine

INN

Anti-tuberculosis medicines

Press release: European Medicines Agency concludes review of dose recommendations for anti-tuberculosis medicines used in children

isoniazide, rifampicine, pyrazinamide, ethambutol, rifabutin

Antifibrinolytics containing medicines

Press release: European Medicines Agency recommends lifting suspension of aprotinin

aprotinin, aminocaproic acid or tranexamic acid

Vivaglobin

human normal immunoglobulin solution for injection (subcutaneous use)

Orlistat-containing medicines
Xenical, Alli, Generics

Press release: European Medicines Agency confirms positive benefit-risk balance of orlistat-containing medicines

orlistat



Safety update

 

Name of medicine

INN

Marketing authorisation holder

Victrelis

Boceprevir

Merck Sharp & Dohme



CHMP recommendation on medication errors

 

Name of medicine

INN

Marketing authorisation holder

Halaven

Eribulin

Eisai Europe Ltd



Other updates

 

Opinions on consultation procedures on ancillary medicinal substances in medicinal devices

Opinions on annual re-assessments and renewals

Opinions on safety variations

Start of Community reviews

Medicines granted a Community marketing authorisation under the centralised procedure since the January CHMP meeting

Overview of invented names reviewed in January 2012 by the Name Review Group (NRG)

Scientific advice and protocol assistance

Guidelines and concept papers adopted during the February 2012 CHMP meeting

Organisational matters

 


 

European Medicines Agency, 17.02.2012 (tB).

 

MEDICAL NEWS

IU School of Medicine researchers develop blood test for anxiety
COVID-19 pandemic increased rates and severity of depression, whether people…
COVID-19: Bacterial co-infection is a major risk factor for death,…
Regenstrief-led study shows enhanced spiritual care improves well-being of ICU…
Hidden bacteria presents a substantial risk of antimicrobial resistance in…

SCHMERZ PAINCARE

Hydromorphon Aristo® long ist das führende Präferenzpräparat bei Tumorschmerz
Sorgen und Versorgen – Schmerzmedizin konkret: „Sorge als identitätsstiftendes Element…
Problem Schmerzmittelkonsum
Post-Covid und Muskelschmerz
Kopfschmerz bei Übergebrauch von Schmerz- oder Migränemitteln

DIABETES

Wie das Dexom G7 abstrakte Zahlen mit Farben greifbar macht…
Diabetes mellitus: eine der großen Volkskrankheiten im Blickpunkt der Schmerzmedizin
Suliqua®: Einfacher hin zu einer guten glykämischen Kontrolle
Menschen mit Diabetes während der Corona-Pandemie unterversorgt? Studie zeigt auffällige…
Suliqua® zur Therapieoptimierung bei unzureichender BOT

ERNÄHRUNG

Positiver Effekt der grünen Mittelmeerdiät auf die Aorta
Natriumaufnahme und Herz-Kreislaufrisiko
Tierwohl-Fleisch aus Deutschland nur mäßig attraktiv in anderen Ländern
Diät: Gehirn verstärkt Signal an Hungersynapsen
Süßigkeiten verändern unser Gehirn

ONKOLOGIE

Strahlentherapie ist oft ebenso effizient wie die OP: Neues vom…
Zanubrutinib bei chronischer lymphatischer Leukämie: Zusatznutzen für bestimmte Betroffene
Eileiter-Entfernung als Vorbeugung gegen Eierstockkrebs akzeptiert
Antibiotika als Störfaktor bei CAR-T-Zell-Therapie
Bauchspeicheldrüsenkrebs: Spezielle Diät kann Erfolg der Chemotherapie beeinflussen

MULTIPLE SKLEROSE

Multiple Sklerose: Aktuelle Immunmodulatoren im Vergleich
Neuer Biomarker für Verlauf von Multipler Sklerose
Multiple Sklerose: Analysen aus Münster erhärten Verdacht gegen das Epstein-Barr-Virus
Aktuelle Daten zu Novartis Ofatumumab und Siponimod bestätigen Vorteil des…
Multiple Sklerose durch das Epstein-Barr-Virus – kommt die MS-Impfung?

PARKINSON

Meilenstein in der Parkinson-Forschung: Neuer Alpha-Synuclein-Test entdeckt die Nervenerkrankung vor…
Neue Erkenntnisse für die Parkinson-Therapie
Cochrane Review: Bewegung hilft, die Schwere von Bewegungssymptomen bei Parkinson…
Technische Innovationen für eine maßgeschneiderte Parkinson-Diagnostik und Therapie
Biomarker und Gene: neue Chancen und Herausforderungen für die Parkinson-Diagnose…